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Background. Early diagnosis of acute kidney injury (AKI) at emergency department (ED) is a challenging issue. Current diagnostic
criteria for AKI poorly recognize early renal dysfunction and may cause delayed diagnosis. We evaluated the use of serum cystatin
C (CysC) for the early and accurate diagnosis of AKI in patients hospitalized from the ED.Methods. In a total of 198 patients (105
males and 93 females), serumCysC, serum creatinine (sCr), and estimated glomerular filtration rate (eGFR) were calculated at 0, 6,
12, 24, 48, and 72 hours after presentation to the ED.We compared two groups according to the presence or absence of AKI. Results.
Serial assessment of CysC, sCr, and eGFR was not a strong, reliable tool to distinguish AKI from non-AKI. CysC > 1.44mg/L at
admission, both alone (Odds Ratio = 5.04; 95%CI 2.20–11.52; 𝑃 < 0.0002) and in combination with sCr and eGFR (Odds Ratio =
5.71; 95%CI 1.86–17.55; 𝑃 < 0.002), was a strong predictor for the risk of AKI. Conclusions. Serial assessment of CysC is not superior
to sCr and eGFR in distinguishing AKI from non-AKI. Admission CysC, both alone and in combination with sCr and eGFR, could
be considered a powerful tool for the prediction of AKI in ED patients.
1. Introduction
Acute kidney injury (AKI) is a common complication in
hospitalized patients [1–4]. Despite progress in medical care,
it is still associatedwith increasedmorbidity,mortality, length
of hospital stay, costs, and postacute care resource utilization
[4, 5]. AKI is defined as a rapid (hours to days) decrease in
renal excretory function with an accumulation of products
of nitrogen metabolism, such as creatinine (sCr), urea, and
other clinically unmeasured waste products [6]. In routine
clinical practice, sCr is used to estimate renal function and,
accordingly, as a marker for diagnosing and staging of AKI
[6, 7].The risk, injury, failure, loss of function, end-stage renal
disease (RIFLE) [8, 9], and the Acute Kidney Injury Network
(AKIN) [10] criteria provide a uniform definition of AKI and
have become the standard for diagnostic criteria [11].
It may be, however, problematic to diagnose AKI in
the patients presented to the emergency department (ED).
Serial assessment of sCr and monitoring of urine output
for several days are necessary for the diagnosis of AKI. In
the ED, however, the baseline sCr level is often unknown
and placement of a urinary catheter may not be indicated,
leading to a delay in diagnosis and, therefore, in adequate
therapy [12]. Moreover, despite evidence of nephron damage,
no diagnostic changes in sCr level may be detected in the
cases of subclinical AKI [13]. As a consequence, there is a
need for new biomarkers that could aid in early diagnosis
and prediction of AKI and, ideally, could be a tool for
discriminating prerenal, intrarenal, or postrenal AKI from
one another, helping in identifying the aetiologies of AKI and
predicting andmonitoring the response to AKI interventions
[14, 15].
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Figure 1: Flow diagram of the study design.
Serum cystatin C (CysC) is freely filtered through the
glomerular membrane and completely reabsorbed and meta-
bolized by the proximal tubular cells without secretion [16,
17]. CysC concentration is affected neither by inflammation,
fever, and/or outside agents nor by muscle mass, gender, or
age [18–21]. Previous studies reported contradictory results
on the accuracy of CysC in the early diagnosis of AKI and
precluded its widespread use as a calculation of estimated
glomerular filtration rate (eGFR) in clinical practice [17, 22–
29]. In this study, we wanted to investigate the potential use of
CysC for the early and accurate diagnosis of AKI, especially in
the patients hospitalized from the ED. We questioned which
would be preferable between single and serial measurements
of CysC, in comparison with sCr and eGFR.
2. Patients and Methods
2.1. Study Population. During the period from November
2008 to April 2009, a total of 203 patients were consecutively
enrolled from the ED of Sant’Andrea Hospital in Rome.
Except for five patients with incomplete data, 198 patients
(105 males and 93 females) were finally included in this study.
Excluded were the patients with a history of marked chronic
renal insufficiency (usual sCr ≥ 3.0mg/dL) or urothelial
malignancy; on dialysis or renal replacement therapy (RRT)
(either acute or chronic); in imminent need of dialysis or RRT
at enrolment; or with a participation history in any inter-
ventional clinical study within the previous 30 days. This
prospective clinical trial was designed following the criteria
of the Declaration of Helsinki and approved by the ethical
committee of the hospital. Written informed consent was
obtained by each patient prior to enrolment.
In all the patients, past medical history and demographic
data were recorded at admission, and routine physical and
laboratory work-ups were performed. Each patient was
treated on the basis of the formulated diagnosis at discretion
of the treating physician, and therapy was carefully recorded.
There were no documented prestudy sCr levels available for
any of the enrolled patients. We calculated a baseline value
for sCr by excluding patients with preexisting chronic kidney
disease (CKD) and by calculating the baseline sCr using the
median values (interquartile range, IQR) measured during
hospital stay, the lowest three of them, that is 0.9 (IQR 0,70–
1.20)mg/dL. Renal dysfunction, the development of oliguria,
the need for a nephrology consultation, initiation of dialysis
or RRT (following international guidelines) [11], intensive
care unit (ICU) admission, and mortality were recorded
during the hospitalization (Figure 1).
2.2. Clinical Adjudication. According to the RIFLE criteria,
all patients were divided into two groups: AKI (𝑛 = 33, 16.7%)
and non-AKI (𝑛 = 165, 83.3%) groups [9, 10]. The renal
function classification and patients’ assignment into the two
groups were performed and confirmed, according to RIFLE
criteria, by the consensus of the Nephrologists of the study
group who were blinded to the biomarker results. AKI was
defined with a new onset of at least 1.5-fold increase of sCr
values from baseline or a eGFR decrease >25%.The non-AKI
group included patients with normal kidney function (NF),
nonprogressive CKD, and prerenal azotemia (PreR). NF was
defined as a baseline eGFR > 60mL/min per 1.73m2 and no
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increase in sCr during the hospitalization. Nonprogressive
CKD was defined as a sustained and unchanging decrease
in eGFR that met criteria for CKD (eGFR < 60mL/min
per 1.73m2) and persisted for more than 3 months before
admission [11]. PreR was defined as a new-onset increase in
sCr that resolvedwithin 48 hours and returned to the baseline
NF level.
2.3.Measurement of CysC, sCr, and eGFR. Renal functionwas
assessed by measuring sCr and CysC. Serial blood samples
were obtained at 0, 6, 12, 24, 48, and 72 hours from presenta-
tion to the ED. After centrifugation at 3,600 rpm for 15 min-
utes, serum samples were stored at −20∘C until used. CysC
was measured by particle enhanced immunonephelometric
assay (N Latex Cystatin C, Siemens,Marburg, Germany), and
itsmeasuring rangewas 0.76mg/L to 1.44mg/L.The results of
CysC were blinded to the medical staffs during the study and
did not affect the management of patients. sCr was measured
by enzymatic assay (Vitros Crea; Ortho Clinical Diagnostics,
High Wycombe, UK), and its normal range was 0.8 to
1.5mg/dL. The biomarker assays were performed following
manufacturer’s instructions. As recommended by Kidney
Disease Outcome Quality Initiative (KDOQI) guidelines,
eGFR was calculated using the modification of diet in renal
disease (MDRD) formula [30–34].
2.4. Statistical Analysis. The results were expressed asmean ±
standard deviation (SD) for normally distributed values or
median and interquartile range for the variables without
normal distribution. The normality of data distribution was
checkedwithD’Agostino and Pearson normality test. Gender,
age, height, weight, BMI, and comorbidities were compared
between AKI and non-AKI groups, using the chi-square test
for categorical variables and one-way analysis of variance for
continuous variables. CysC, Cr, and eGFR were compared
between AKI and non-AKI groups using Mann-Whitney 𝑈
test and Kruskall-Wallis test. A logistic univariate model was
used to select the variables most predictive of AKI develop-
ment. Odds ratios (OR) with 95% confidence interval (CI)
were calculated using theWald method. A receiver operating
characteristic (ROC) curve was utilized to determine the
ability of CysC, sCr, and eGFR at 𝑇0 to predict AKI. The
area under curve (AUC) indicated the predictive value of each
biomarker (𝑃 value < 0.05 was considered statistically signif-
icant).
3. Results
Patients’ characteristics are presented in Table 1. There was
no statistical difference in the distribution of gender, age,
and body mass index (BMI) between the two groups. Except
for chronic obstructive pulmonary disease (𝑃 < 0.001), the
distribution of comorbidities did not differ between the two
groups. Mean infusion volume was 950 milliliters/daily, and
mean urine outputwas 1250milliliters/daily with amean fluid
balance of −300 milliliters in the first 24 hours.
Figure 2 shows the serial comparison of CysC, sCr, and
eGFR between AKI and non-AKI groups. When considering
serial measurements and the comparison of AKI versus non-
AKI, CysC and sCr showed significant differences between
the two groups at each measurement time until 48 hours.
eGFR also showed such a significant difference from admis-
sion until 24 hours.
When only AKI group was evaluated, all the three
markers, CysC, sCr, and eGFR, did not show any statistical
difference, according to the time course, and the same was
for non-AKI group. In patients with AKI the 1.5-fold increase
of sCr was at amean of 37.6 ± 23 (hours ± SD) after admission
in ED.
In univariate analysis, CysC, sCr, and eGFR at admission
were compared for the prediction of AKI development, and,
moreover, their combination was evaluated. Admission CysC
level > 1.44mg/L was strongly related to the increased risk
of AKI development (OR = 5.04; 95% CI, 2.20–11.52; 𝑃 <
0.0002). sCr level > 1.5mg/dL (OR = 2.84; 95% CI, 1.26–6.37;
𝑃 < 0.01) and eGFR < 60mL/min/1.73m2 (OR = 3.33; 95%
CI, 1.50–7.38; 𝑃 < 0.003) were also related to the increased
risk of AKI, but not strongly. The best predictive model for
AKI development was the combined use of CysC, sCr, and
eGFR at admission (OR= 5.71; 95%CI, 1.86–17.55;𝑃 < 0.002);
the combination of CysC + sCr had an OR = 3.48 (95% CI,
1.70–7.01, 𝑃 < 0.01), and the combination of CysC + eGFR
had an OR = 4.35 (95% CI, 1.68–8.12, 𝑃 < 0.02) (Table 2).
A ROC curve analysis was performed for CysC, sCr,
and eGFR at admission. We evaluated ROC prognostic value
of the markers both alone and in combination. The AUC
of CysC compared to sCr and to eGFR showed a higher
predictive power (CysC= 0.72,𝑃 < 0.02; sCr = 0.70,𝑃 < 0.01;
eGFR=0.71,𝑃 < 0.01).TheAUCofCysC+ sCr andofCysC+
eGFR showed a good high diagnostic value for AKI (resp.,
AUC 0.70, 𝑃 < 0.0004, and AUC 0.70, 𝑃 < 0.0003) but lower
than that of CysC alone.
4. Discussion
The early diagnosis of AKI in ED is a challenging issue. The
current diagnosis of AKI is based on the serial measurement
of sCr and/or the monitoring of urinary output [6, 7].
sCr is greatly influenced by several renal and nonrenal
factors, including changes in muscle mass, tubular secretion,
extracellular fluid volume expansion, malnutrition, race, age,
gender, and medications [35–37]. Moreover, it is difficult
to carefully collect and monitor urine output in ED. These
factors could hamper the detection of sCr increase despite
significant kidney injury and delay the diagnosis of AKI [38].
Many biomarkers have been studied to solve this problem
and, among them, CysC has got an increasing attention
recently.
CysC is produced at a constant rate by all nucleated cells
and its concentration is not influenced by age, sex, height,
and body composition. Accordingly, CysC concentration
reflects only the balance of its primary physiological deter-
minants: cellular generation, renal filtration, and subsequent
renal degradation [16–21]. An increased CysC concentration
identifies early deviations in eGFR and, subsequently, a
“preclinical” state of kidney dysfunction that is not detected
with sCr or eGFR [21].
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Table 1: Patients’ characteristics.
Total AKI group Non-AKI group
(𝑛 = 198) (𝑛 = 33, 16.7%) (𝑛 = 165, 83.3%)
Male/female (𝑛) 105/93 18/15 81/84
Age (years) 74 ± 13.6 73 ± 14.0 78 ± 10.4
Height (cm) 165.7 ± 8.8 166.0 ± 8.0 166.0 ± 9.0
Weight (kg) 72.9 ± 15.7 74.0 ± 17.0 73.0 ± 15.0
BMI (kg/m2) 26.5 ± 5.1 26.9 ± 5.4 26.4 ± 5.0
Comorbidities (𝑛, %)
Coronary artery disease 53 (26.8) 8 (24.2) 45 (27.3)
Hypertension 125 (63.1) 23 (69.7) 99 (60.0)
Dyslipidemia 26 (13.1) 4 (12.1) 21 (12.7)
Arrhythmia 55 (27.8) 10 (30.3) 45 (27.3)
Pacemaker 14 (7.1) 4 (12.1) 8 (4.8)
Valvulopathies 12 (6.1) 2 (6.1) 10 (6.1)
COPD 65 (32.8) 19 (57.6) 46 (27.9)∗
Diabetes 57 (28.8) 9 (27.3) 46 (27.9)
Chronic kidney disease 22 (11.1) 5 (15.2) 17 (10.3)
Anemia 18 (9.1) 4 (12.1) 13 (7.9)
Stroke/TIA 24 (12.1) 3 (9.1) 20 (12.1)
Pulmonary embolism 2 (1.0) 1 (3.0) 1 (0.6)
∗
𝑃 < 0.0001 versus AKI group.
Data are expressed as mean ± standard deviation or number (percentage).
AKI, acute kidney injury; BMI, body mass index; COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack.
The previous studies on CysC were mostly conducted
in specific clinical settings (i.e., department of nephrology,
coronary care unit, and ICU) with relatively homogeneous
and selected study populations. Moreover, the literature data
are based on only one measurement of CysC at baseline. In
the ED, such studies on CysC have been limited. Nickolas
et al. [13] demonstrated that urinary CysC had a slight
predictive power on diagnosis of AKI in ED. In 2010 Soto et al.
published a study conducted in a nonsurgical ED, evaluating
serum and urinary Cr and CysC at several times from ED
presentation in 800 consecutive patients. They concluded on
behalf of CysC as a better and earlier predictive biomarker
of AKI than sCr [20]. Differently, in our study, a smaller
and more heterogeneous sample was evaluated, and they
were both surgical and nonsurgical patients. As a matter of
fact, our results showed that there are statistically significant
differences among the two groups (AKI versus non-AKI) for
CysC values at several times (admission, 6 hours, 12 hours,
and 48 hours) but the same results were found for sCr values
(admission, 6 hours, 12 hours, 24 hours, and 48 hours) and
eGFR values (admission, 6 hours, 12 hours, and 24 hours)
confirming that the traditional methods used, nowadays, are
enough for the detection of AKI.
However, their serial assessment did not show any signif-
icant difference according to the time course in each group
[20]. Compared with the traditional markers of sCr and
eGFR, CysC did not show any advantage for the prediction of
AKI (Figure 2). Noticeably, we found that CysC > 1.44mg/L
at admission had a greater power in predicting AKI (OR =
5.04) than sCr (OR=2.84) and eGFR (OR=3.33). In addition,
Table 2: Univariate analysis of CysC, sCr, and eGFR at admission
for the risk of acute kidney injury development.
OR 95% CI 𝑃 value
CysC 5.04 2.20–11.52 0.0002
sCr 2.84 1.26–6.37 0.01
eGFR 3.33 1.50–7.38 0.003
CysC + sCr 3.48 1.70–7.01 0.01
CysC + eGFR 4.35 1.68–8.12 0.002
CysC + sCr + eGFR 5.71 1.86–17.55 0.002
CysC, cystatinC; eGFR, estimated glomerular filtration rate; sCr, serum
creatinine; OR, odds ratio; CI, confidence interval.
the combined use of CysC, sCr, and eGFR at admission
showed the best result for the prediction of AKI (Table 2).
ROC curve analysis confirmed the higher diagnostic
power of CysC, not only when combined with the other
two markers, but also alone; this indicates probably a more
diagnostic accuracy of CysC in comparison with sCr and
eGFR, also if the serial measurements showed the same
statistical significance in the AKI versus non-AKI group for
all the three markers studied.
This study is limited in that relatively smaller and more
heterogeneous patients were enrolled and they were both
surgical and nonsurgical patients that could have caused a
wide variability ofmeasured data, especially for Cr.Moreover,
patients with Cr> 3mg/dLwere excluded from the study, and
the patientswere not followedup.TheEDpopulation is one of
the most difficult groups in which to define the baseline time
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Figure 2: Serial comparison of CysC, sCr, and eGFR between AKI and non-AKI groups.
with respect to the development of the clinical problem.
However, in the ED, the diagnosis and risk prediction of
AKI are made in these heterogeneous populations without
enough data fulfilling the diagnostic criteria, and our study
population may simulate the general population afferent to
the ED for various acute conditions.
In conclusion, we investigated the potential use of CysC
for the diagnosis of AKI in the patients presented to the
ED. Our data demonstrates that the serial assessment of
CysC does not provide additional value for the diagnosis
of AKI, as well as Cr and eGFR. On the contrary, an
elevated CysC concentration is associated with a higher risk
of developing AKI in the general population afferent to the
ED. Measurement of CysC at admission, alone or combined
with Cr and eGFR, is a preferable option for the prediction
of AKI in the ED. Larger studies are awaited to support
the present findings and to define the specific role of serum
CysC in AKI.
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